



EUROPEAN DRUG UTILISATION RESEARCH GROUP CONFERENCE 2017

Patients, Medicines, Bytes:
Drug Utilisation Research and E-health



PROGRAMME BOOK

Wednesday 15th - Friday 17th November 2017

Technology & Innovation Centre

University of Strathclyde, Glasgow UK





EUROPEAN DRUG UTILISATION RESEARCH GROUP CONFERENCE 2017

sponsored by



Dear colleagues,

On behalf of the Scientific and Local Organising Committees we extend a warm welcome to Glasgow, Scotland for the EuroDURG 2017 Scientific Meeting. Healthcare and medication use are changing and the field of drug utilisation research is evolving in a digital world. For this reason we chose as our theme for this meeting: **Patients, Medicines, Bytes: Drug Utilisation Research and E-health.**

The European branch of the ISPE Special Interest Group for Drug Utilisation Research has designed an attractive educational and scientific programme. We start with a half day of educational sessions on drug utilisation research by leading experts from across Europe and more globally. This will be followed by a broad range of plenary sessions on digital health technology, big data informatics and global health policy interspersed with workshops and sessions exploring new methodological approaches and drug use research in a wide range of clinical areas to drive improvement in the real world use of medicines.

We hope you will join us in lively discussions throughout the meeting and at the poster walk sessions on Thursday and Friday. EuroDURG meetings traditionally combine great scientific content with surprising social events. So come to the conference welcome reception, hosted at our historic City Chambers, and our conference dinner at the Glasgow Science Centre, on the banks of the Clyde River and experience a Scottish ceilidh.

Marion Bennie

Chair, Local Organising Committee



Katja Taxis

Chair, Scientific Committee



LOCAL ORGANISING COMMITTEE

Marion Bennie (Chair) ¹
Samantha Alvarez Madrazo¹
Emma Dunlop Corcoran¹
Monique Elseviers
Anja Fischer²
Brian Godman¹
Amanj Kurdi¹
Ellie Quinn¹
Katja Taxis

¹University of Strathclyde

²Abbey Conference & Events

SCIENTIFIC COMMITTEE

Katja Taxis, The Netherlands (Chair)
Marion Bennie, UK
Anna Birna Almarsdottir, Denmark
Ria Benko, Hungary
Matt-Mouley Bouamrane, UK
Monique Elseviers, Belgium
Brian Godman, UK / Sweden
Jolanta Gulbonovic, Lithuania
Simon Hurding, UK
Janet Krska, UK
Paraskevi Voula Papaioannidou, Greece
Elisabetta Poluzzi, Italy
Lisa Pont, Australia
Jane Robertson, WHO

Margaret Ryan, UK
Gabriel Sanf  lix-Gimeno, Spain
Gisbert W. Selke, Germany
Catherina Sermet, France
Fatima Suleman, South Africa
Robert Vander Stichele, Belgium
Bj  rn Wettermark, Sweden
Veronika Wirtz, USA

WEDNESDAY		MAIN AUDITORIUM B	MAIN AUDITORIUM C	ROOMS 6 & 7
	09:00 – 10:30	<u>E1W</u> CNC of Drug Utilization	<u>E2W</u> Time Series Analysis	<u>E3W</u> Data Sources – Validation Research
	10:30 – 11:00	<i>Coffee Break</i>		
	11:00 – 12:30	<u>E4W</u> Adherence Research Using Databases	<u>E5W</u> Quality of Quality Indicators	<u>E6W</u> Using Field Studies in DUR
	12:30 – 13:30	<i>Lunch Break</i>		
		SCIENTIFIC PROGRAMME PART I		
	13:30 – 15:00	Welcome & Keynote Lectures <u>K1W</u> Digital - The Future is Here, Gillian Docherty <u>K2W</u> Digitalizing and DUR: Challenges and Opportunities, Björn Wettermark		
	15:00 – 16:00	<i>Coffee Break</i>		
	16:00 – 17:30	<u>P1W</u> Antimicrobial Use and Resistance	<u>P2W</u> ePrescribing and eDispensing Systems	<u>P3W</u> Adherence
	19:00	<i>Welcome Reception: City Chambers, Glasgow</i>		

THURSDAY		MAIN AUDITORIUM B	MAIN AUDITORIUM C	ROOMS 6 & 7
		SCIENTIFIC PROGRAMME PART II		
	08:30 – 10:00	<u>P4T</u> Prescribing and de-Prescribing in Old Age	<u>P5T</u> Gender Difference and Safety in DU	<u>P6T</u> Decision Support to Improve Drug Use
	10:00 – 10:30	<i>Coffee Break</i>		
	10:30 – 12:00	<u>P7T</u> Globalization of DUR	<u>P8T</u> Drug Use in Pregnancy and Peadiatrics	<u>P9T</u> Evolving Methods in DUR
	12:00 – 13:00	<i>Lunch Break</i>		
		SCIENTIFIC PROGRAMME PART III		
	13:00 – 14:30	<u>W1T</u> DUR on the Life Cycle of Drugs	<u>S2T</u> Data Visualization	<u>W3T</u> From Intervention to Implementation How Can Science Help?
	14:30 – 16:00	<i>Coffee Break/ 14:45 Poster Walk</i>		
	16:00 – 17:30	Keynote Lectures <u>K3T</u> Taking a “Molecule to Man” Approach, Andrew Morris <u>K4T</u> The Patient and Public Voice – Using Big Data for Public Benefit, Sarah Cunningham-Burley		
	17:30 – 18:30	<i>EuroDURG General Assembly</i>		
	19:30	<i>EuroDURG Networking Dinner: Glasgow Science Centre</i>		

		MAIN AUDITORIUM B	MAIN AUDITORIUM C	ROOMS 6 & 7
		SCIENTIFIC PROGRAMME PART IV		
FRIDAY	08:30 – 10:00	<u>P10F</u> Inform and Evaluate Health Policy	<u>P11F</u> Citizen Science and DUR	<u>P12F</u> Cardiovascular Therapy
	10:00 – 10:30	<i>Coffee Break</i>		
	10:30 – 12:00	<u>P13F</u> Patient Reported Outcome Measures	<u>P14F</u> New Medicines: Management of Innovations	<u>P15F</u> DUR Across the World
	12:00 – 13:00	<i>Lunch Break</i>		
		SCIENTIFIC PROGRAMME PART V		
	13:00 – 14:30	<u>S4F</u> Predictive Analytics, Patient Level Drug Exposure	<u>W5F</u> Role of DUR in Comparative Effectiveness Research	<u>W6F</u> Cross-National Comparison Guideline and Checklist
	14:30 – 16:00	<i>Coffee Break / 14:45 Poster Walk</i>		
	16:00 – 17:30	Keynote Lecture <u>K5F</u> Drug Utilization and Health Policy from a Global Perspective, Katja Taxis, Veronika Wirtz, Lisa Pont Closing Ceremony		

E = Educational Session

K = Keynote Lecture

P = Parallel Session

S = Symposium

W = Workshop



TABLE OF CONTENTS

PROGRAM

Wednesday 15th November 7

Thursday 16th November 11

Friday 17th November 15

SOCIAL PROGRAM 20

CONFERENCE & EVENT LOCATION AND FACILITIES 21

LIST OF POSTER ABSTRACTS 24

NOTES 31

PROGRAM: WEDNESDAY 15TH NOVEMBER

09:00 – 10:30		EDUCATIONAL SESSION E1W <i>Cross-National Comparison of Drug Utilization</i>	
MAIN AUDITORIUM B		CHAIR: Monique Elseviers, Belgium	CHAIR: Aukje Mantel-Teeuwisse, The Netherlands
AIMS - To demonstrate the problems encountered while comparing DU data of different countries - To give a global overview of the CNC guideline - To focus on sources of bias in designing a CNC study - To focus on sources of bias in conducting a CNC study			
SPEAKER		Monique Elseviers, Belgium <i>Introduction: Pitfalls of cross-national comparison (CNC) studies</i>	
SPEAKER		Yared Santa Ana-Tellez, Spain / Mexico <i>Development and lay-out of the CNC guideline</i>	
SPEAKER		Robert Vander Stichele, Belgium <i>Sources of bias in conducting a CNC study</i>	
SPEAKER		Yared Santa Ana-Tellez, Spain / Mexico <i>Sources of bias in designing a CNC study</i>	

09:00 – 10:30		EDUCATIONAL SESSION E2W <i>Time Series Analysis</i>	
MAIN AUDITORIUM C		CHAIR: Gisbert W. Selke, Germany	CHAIR: Peter Mol, The Netherlands
AIMS Focusing on the use of large, usually secondary, data sets, the session will present an introduction to the field as well as methods to address the particular problems encountered in longitudinal research, such as the impact of (possibly multiple) interventions and auto-correlations in the observations.			
SPEAKER		Gisbert W. Selke, Germany <i>Introduction to time series analysis</i>	
SPEAKER		Peter Mol, The Netherlands <i>Interrupted time series analyses applied to study impact of safety communication about medicine</i>	
SPEAKER		Joris Komen, The Netherlands <i>Dealing with auto-correlation and seasonality in time series</i>	

09:00 – 10:30		EDUCATIONAL SESSION E3W <i>Data Sources – Validation Research</i>	
ROOMS 6 & 7		CHAIR: Helga Gardarsdottir, The Netherlands	CHAIR: Tatiana Chama Borges Luz, Brazil
AIMS To give insights into methods that are applied to different data sources to assess drug exposure, how these relate to actual patient drug use and how exposure assessment definition influences outcome estimates.			
SPEAKER		Helga Gardarsdottir, The Netherlands <i>Comparisons of methods used to assess drug exposures in observational data</i>	
SPEAKER		Antti Tanskanen, Finland <i>Validation of exposure assessment using mathematical modelling and expert review: The PRE2DUP method</i>	
SPEAKER		Luisa Ibáñez, Spain <i>Validation of clinical outcomes in observational studies</i>	

11:00 – 12:30	EDUCATIONAL SESSION E4W <i>Adherence Research Using Databases</i>	
MAIN AUDITORIUM B	CHAIR: Anna Birna Almarsdottir, Denmark	CHAIR: Gabriel Sanf��lix-Gimeno, Spain
AIMS The aims are to introduce participants to medication adherence concepts and methodologies used to assess drug exposure using electronic databases, and to give insights into the assumptions and challenges faced when describing patterns of medication consumption.		
SPEAKER	Anna Birna Almarsdottir & Gabriel Sanf��lix-Gimeno <i>Introduction to adherence: definition, concepts and importance</i>	
SPEAKER	Rob Heerdink, The Netherlands <i>Assessing adherence using electronic databases: measures, assumptions, and exposure definition</i>	
SPEAKER	Emma Aarnio, Finland <i>Trajectory modelling and its challenges when measuring adherence with databases</i>	
11:00 – 12:30	EDUCATIONAL SESSION E5W <i>Quality of Quality Indicators</i>	
MAIN AUDITORIUM C	CHAIR: Brian Godman, Sweden / UK	CHAIR: Jane Robertson, WHO
AIMS Discuss the development of QIs within healthcare systems and potential ways to assess their rationale and the ability to achieve the desired outcome.		
SPEAKER	Stephen Campbell, UK <i>Outline of QIs, their development and key considerations for measuring their quality</i>	
SPEAKER	Jane Robertson, WHO <i>Potential indicators to assess the quality of antibiotic use across Europe</i>	
SPEAKER	Se��n Macbride-Stewart, UK <i>Quality Prescribing Indicators – Scotland’s experience</i>	
11:00 – 12:30	EDUCATIONAL SESSION E6W <i>Using Field Studies in Drug Utilization Research</i>	
ROOMS 6 & 7	CHAIR: Katja Taxis, The Netherlands	CHAIR: Veronika Wirtz, USA
AIMS - To analyse common study designs of pharmacoepidemiologic studies without large databases - To discuss strengths and limitations of different study designs and data collection methods - To identify strategies to improve quality and reliability of pharmacoepidemiological studies conducted without large databases		
SPEAKER	Katja Taxis, The Netherlands <i>Data collection through questionnaires and observation</i>	
SPEAKER	Lisa Pont, Australia <i>Examples of studies done without large databases</i>	
SPEAKER	Annie Fourrier-R��glat, France <i>Introduction and overview of study designs</i>	

SCIENTIFIC PROGRAMME PART I

13:30 – 15:00	WELCOME CEREMONY	
MAIN AUDITORIUM B & C	CHAIR: Marion Bennie, UK	CHAIR: Katja Taxis, The Netherlands
SPEAKER	Tim Bedford, Associate Principal Research and Innovation, University of Strathclyde, UK	
MAIN AUDITORIUM B & C	KEYNOTE LECTURES K1W & K2W	
SPEAKER	an Docherty, Chief Executive Officer, The Data Lab, Scotland , UK <i>Digital - The future is here</i>	
SPEAKER	Björn Wettermark, Sweden <i>Digitalizing and DUR: challenges and opportunities</i>	

16:00 – 17:30	PARALLEL SESSION P1W <i>Antimicrobial Use and Resistance</i>	
MAIN AUDITORIUM B	CHAIR: Ria Benko, Hungary	CHAIR: Jane Robertson, WHO
AIMS To show effective interventions which result in more prudent antibiotic use in ambulatory care.		
SPEAKER	Carl Llor, Spain <i>Evidence-based interventions addressed to prescribe antibiotics more prudently in ambulatory care</i>	
P1W.1	Ria Benko, University Of Szeged, Hungary <i>The pattern of antibiotic use among Hungarian, Norwegian and Portuguese children</i>	
P1W.2	William Malcolm, Health Protection Scotland, NHS National Services Scotland, Glasgow, UK <i>Measuring potential adverse consequences of restricting antibiotic treatment of respiratory tract infections in primary care: a population data linkage study using NHS Scotland's Infection Intelligence Platform</i>	
P1W.3	Michael Fleming, Health Protection Scotland NHS National Services Scotland, Glasgow, UK <i>Characterisation of risk factors associated with antibiotic resistance in urinary isolates in the community: an exemplar of NHS Scotland's Infection Intelligence Platform</i>	
P1W.4	Verica Ivanovska, Faculty of Medical Sciences, Stip, Macedonia, Utrecht University Netherlands, Utrecht, The Netherlands <i>Impact of the national intervention programme on parental knowledge, attitudes and practice of antibiotic use for respiratory infections</i>	

16:00 – 17:30	PARALLEL SESSION P2W <i>ePrescribing and eDispensing Systems</i>	
MAIN AUDITORIUM C	CHAIR: Matt-Mouley Bouamrane, UK	CHAIR: Robert Vander Stichele, Belgium
AIMS This session will include presentations from leading experts in the field of ePrescribing / eDispensing implementation and evaluation which will provide fundamental information for all of those interested in adopting and deploying these solutions in future.		
SPEAKER	Robert Vander Stichele, Belgium <i>Short intro into the terminology and the interoperativity of systems</i>	
SPEAKER	Abby King, UK <i>ePrescribing toolkit for NHS hospitals in England</i>	
SPEAKER	Alison Strath, UK <i>Scotland ePharmacy programme</i>	

P2W.1	Marion Bennie, NHS National Services Scotland / University of Strathclyde, UK <i>Analysis of risk factors for bacteraemia and subsequent mortality in Scotland: a national data linkage matched case-control study using NHS Scotland's Infection Intelligence Platform</i>
--------------	--

16:00 – 17:30	PARALLEL SESSION P3W <i>Adherence</i>	
ROOMS 6 & 7	CHAIR: Monique Elseviers, Belgium	CHAIR: Bernard Vrijens, Belgium
AIMS • To stress the importance of the three while speaking about adherence • To present different methods to measure adherence focusing on current electronic developments and the availability of big data • To evaluate the added value and the limitations of database research in the field of adherence research		
SPEAKER	Bernard Vrijens, Belgium <i>Adherence research & big data: strengths and limitations</i>	
P3W.1	Enrica Menditto, CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy <i>A snapshot of medication adherence across three European countries: application of common methodology.</i>	
P3W.2	Daniel Bejarano-Quisoboni, Center for Public Health Research (CSISP-FISABIO), Valencia, Spain <i>Adherence trajectories to essential medications and clinical outcomes after acute coronary syndrome. A population-based cohort study</i>	
P3W.3	Alexandra Lelia Dima, Health Services and Performance Research (HESPER), Université Claude Bernard Lyon 1, France <i>Introducing adhere R: an R package for visualization of medication histories and calculation of adherence to medications using electronic healthcare data</i>	
P3W.4	Johanna Meyer, School of Pharmacy, Sefako Makgatho Health Sciences University, Ga-Rankuwa, Pretoria, South Africa <i>Adherence to antiretroviral treatment amongst patients in Botswana: A multi-measure approach to guide future practice</i>	

PROGRAM: THURSDAY 16TH NOVEMBER

SCIENTIFIC PROGRAM PART II

08:30 – 10:00	PARALLEL SESSION P4T <i>Prescribing and de-Prescribing in Old Age</i>	
MAIN AUDITORIUM B	CHAIR: Monique Elseviers, Belgium	CHAIR: Lisa Pont, Australia
AIMS - To highlight the specific position of de-prescribing as an additional tool to tackle polypharmacy and associated negative outcome in old age - To handle the current evidence of medications, candidate for de-prescribing - To offer guidance in the practice of communicating de-prescribing with de patient and his caregivers/family		
SPEAKER	Bruce Guthrie, UK <i>Reducing high-risk prescribing and optimising prescribing in people with polypharmacy</i>	
P4T.1	Christina Raae-Hansen, Pharmaceutical Care Research Group, School of Pharmacy, University College Cork (UCC), Cork, Ireland <i>Trends of potentially inappropriate prescribing in early old aged people over a 5-year period</i>	
P4T.2	Edwin Tan, Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden, Centre for Medicine Use and Safety, Monash University, Parkville, Australia <i>Antihypertensive medication regimen intensity and incident dementia in an older population</i>	
P4T.3	Marie-laure Laroche, Centre of Pharmacovigilance and Pharmacoepidemiology, Limoges, France <i>Prescription of futile and essential drugs in the last three months of life of older patients receiving palliative care</i>	
P4T.4	Hans Wouters, Dept. Of Pharmacotherapy, -Epidemiology & -Economics, University Of Groningen, Groningen, The Netherlands, Dept. Of General Practice And Elderly Care Medicine, University Medical Center Groningen, Groningen, The Netherlands <i>Discontinuing inappropriate medication in nursing home residents (DIM-NHR study): a cluster randomized controlled trial</i>	

08:30 – 10:00	PARALLEL SESSION P5T <i>Gender Difference and Safety in DU</i>	
MAIN AUDITORIUM C	CHAIR: Jolanta Gulbonovic, Lithuania	CHAIR: Petra Denig, The Netherlands
AIMS To present an overview of gender related differences in drug utilization and drug safety; to explore the potential opportunities and challenges studying the reasons and consequences of these differences.		
SPEAKER	Ylva Böttiger, Sweden <i>Differences in prescribing to women and men: sex or gender?</i>	
SPEAKER	Petra Denig, The Netherlands <i>Differences in side effects between women and men: sex or gender?</i>	
P5T.1	Andréia Turmina Fontanella, Graduate Studies Program in Epidemiology, School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil <i>Psychotropic drug use and the differences between men and women: results from a household survey</i>	
P5T.2	Gisbert W. Selke, Wissenschaftliches Institut der AOK, Berlin, Germany <i>Concerns regarding the safety of combined hormonal contraceptives: influence of an EU risk assessment process on prescription patterns. An analysis of German claims data 2011–2015</i>	

08:30 – 10:00	PARALLEL SESSION P6T <i>Decision Support to Improve Drug Use</i>	
ROOMS 6 & 7	CHAIR: Robert Vander Stichele, Belgium	CHAIR: Catherine Sermet, France
AIMS To provide an overview of the characteristics of point-of-care knowledge databases, the available evidence of impact.		
SPEAKER	Stijn Van De Velde, Norway <i>Guidelines for implementation of decision support systems</i>	
P6T.1	Rianne Weersink, University of Groningen, Groningen, the Netherlands, Health Base Foundation, Houten, The Netherlands <i>Developing advices for safe drug use in patients with liver cirrhosis</i>	
P6T.2	Helene van der Meer, University Of Groningen, Groningen, The Netherlands <i>Latent class analysis of anticholinergic and sedative medication use: a national population study</i>	
P6T.3	Heshu Abdullah-koolmees, UMC Utrecht, Utrecht, The Netherlands, Utrecht University, Utrecht, The Netherlands <i>Predicting rehospitalization in patients treated with antipsychotics: a prospective observational study</i>	
P6T.4	Janet Krska, Medway School of Pharmacy, Universities of Greenwich and Kent, Chatham Maritime, UK <i>Development and testing of the Side Effects Patient Assessment Tool (SE-PAST)</i>	

10:30 – 12:00	PARALLEL SESSION P7T <i>Globalization of DUR</i>	
MAIN AUDITORIUM B	CHAIR: Robert Vander Stichele, Belgium	CHAIR: Aukje Mantel-Teeuwisse, The Netherlands
AIMS To give a global perspective of DUR by discussing state of DUR and challenges outside Europe.		
SPEAKER	Claudia Garcia Serpa Osorio-de-Castro, Brazil <i>Exploring federal data on medicines procurement in Brazil</i>	
SPEAKER	Fatima Suleman, South Africa <i>Global drug utilization review: what's happening in Africa</i>	
SPEAKER	Debra Rowett, Australia <i>Predicted versus actual analysis of listed medicines- a routine part of national drug utilization review</i>	

10:30 – 12:00	PARALLEL SESSION P8T <i>Drug Use in Pregnancy and Paediatrics</i>	
MAIN AUDITORIUM C	CHAIR: Elisabetta Poluzzi, Italy	CHAIR: Hedvig Nordeng, Norway
AIMS - To describe updates in methods of DU studies focusing on paediatric population and pregnancy - To map sources of data and their limitations in this field - To highlight future challenges in DU studies for these populations		
SPEAKER	Hedvig Nordeng, Norway <i>Drug utilisation in pregnancy – a multinational perspective</i>	
SPEAKER	Elisabetta Poluzzi, Italy <i>Drug utilisation in paediatrics – different challenges for different age groups</i>	

P8T.1	Pierre-Olivier Blotiere, Department of Studies in Public Health, French National Health Insurance (CNAMTS), France <i>Risks of specific major congenital malformations associated with prenatal exposure to antiepileptic drugs: a nationwide cohort study based on the French healthcare databases</i>
P8T.2	Elin Dahlén, Department of Healthcare Development, The Health and Medical Care Administration, Stockholm County Council, Sweden <i>Health care utilization and dispensed medicines among children in Stockholm, Sweden</i>

10:30 – 12:00	PARALLEL SESSION P9T <i>Evolving Methods in DUR</i>	
ROOMS 6 & 7	CHAIR: Björn Wettermark, Sweden	CHAIR: Marion Bennie, UK
AIMS To describe the evolving methods in drug utilization research.		
P9T.1	Clifford Nangle, University Of Dundee, Dundee, UK, NHS National Services Scotland, Edinburgh, UK <i>Modelling free-text prescription dose instructions to support daily dosage calculation</i>	
P9T.2	Job FM Van Boven, Department of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands <i>Dynamics of discontinuation in new metformin users in the first year of treatment</i>	
P9T.3	Catherine Sermet, Irdes, Paris, France <i>Measuring polypharmacy in the elderly on a French national health database: impact of calculation method on prevalence and therapeutic classes</i>	
P9T.4	Mikael Hoffmann, The Nepi Foundation, Linköping, Sweden <i>National monthly standard-reports of incidence-rates of drugs in Sweden – development process, validation and results</i>	
P9T.5	Chris Johnson, Pharmacy & Prescribing Support Unit, NHS Greater Glasgow & Clyde, Glasgow, UK <i>‘Doing the right thing’: Factors influencing GP prescribing of antidepressants and prescribed doses</i>	
P9T.6	Sandy Maumus-Robert, Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Bordeaux, France <i>Off-label use of oral morphine sulfate for opioid maintenance purpose in France: results from the 2009-2015 UTOPIA study</i>	

SCIENTIFIC PROGRAMME PART III

13:00 – 14:30	WORKSHOP W1T <i>DUR on the Life Cycle of Drugs</i>	
MAIN AUDITORIUM B	CHAIR: Björn Wettermark, Sweden	CHAIR: Debra Rowett, Australia
AIMS To explore how drug utilization studies can contribute to improve lifecycle management of new medicines, using the new lipid lowering drugs as an example.		
SPEAKER	Björn Wettermark, Sweden <i>What can we learn from drug utilization studies on statins – Overview of studies on prescribing patterns, rational use and patient adherence to statin therapy in different populations</i>	
SPEAKER	Peter Mol, The Netherlands <i>Introduction to the PCSK9 inhibitors. Challenges from a regulatory and a payer perspective</i>	

13:00 – 14:30	SYMPOSIUM S2T <i>Data Visualisation</i>	
MAIN AUDITORIUM C	CHAIR: Ria Benko, Hungary	CHAIR: Gisbert W. Selke, Germany
AIMS To be able to design meaningful diagrams for different contexts and varying audiences, and to become familiar with methods for visualising large data sets and high-dimensional data, both statically and interactively.		
SPEAKER	Seán Macbride-Stewart, UK <i>Want to influence prescribing? Make it easy for prescribers to interpret prescription data</i>	
SPEAKER	Maria Matuz, Hungary <i>Visualisation of DU data in the scientific literature</i>	
SPEAKER	Mikael Hoffmann, Sweden <i>Interactive visualization of drug utilization data – why, how, when, and when not</i>	

13:00 – 14:30	WORKSHOP W3T <i>From Intervention to Implementation – How Can Science Help?</i>	
ROOMS 6 & 7	CHAIR: Marion Bennie, UK	CHAIR: Lisa Pont, Australia
AIMS To explore how implementation science can be applied to support understanding of the key elements necessary to achieve success in moving from a health intervention study to widespread diffusion across a healthcare system.		
SPEAKER	Rachel Bruce, UK <i>Implementation science – the why, what and how?</i>	

14:45 – 16:00	POSTER WALK <i>Each poster has 3 minutes to present, followed by 2 minutes of discussion</i>	
1. Antibiotics (A)	Chairperson: Jane Robertson, Kotoji Iwamoto	
2. Cardiovascular (A)	Chairperson: Elisabetta Poluzzi, Tanja Mueller	
3. Cancer and Biologicals (A)	Chairperson: Anna Birna Almarsdottir, Helga Gardarsdottir	
4. Drug Policy (A)	Chairperson: Gisbert W. Selke, Claudia Osario	
5. Elderly (A)	Chairperson: Robert Vander Stichele, Debra Rowett	
6. Nervous System (A)	Chairperson: Gabriel Sanfelix-Gimeno, Yared Santa-Ana Téllez	
7. Diabetes	Chairperson: Luisa Ibáñez	
8. Interventions	Chairperson: Björn Wettermark	
9. Respiratory and Safety	Chairperson: Jolanta Gulbonovic, Renata Macedo	

16:00 – 17:30	KEYNOTE LECTURES K3T & K4T	
MAIN AUDITORIUM B & C	CHAIR: Marion Bennie, UK	
SPEAKER	Andrew Morris, Professor of Medicine, Director of Health Data Research UK, the National Health and Biomedical Informatics Institute, UK <i>Health informatics – taking a “molecule to man” approach</i>	
SPEAKER	Sarah Cunningham-Burley, Professor of Medical and Family Sociology, Farr Scotland Public Involvement Lead, UK <i>Patient perspective – The patient and public voice – using big data for public benefit</i>	

PROGRAM: FRIDAY 17th NOVEMBER

SCIENTIFIC PROGRAMME PART IV

08:30 – 10:00	PARALLEL SESSION P10F <i>Inform and Evaluate Health Policy</i>	
MAIN AUDITORIUM B	CHAIR: Brian Godman, Sweden / UK	CHAIR: Simon Hurding, UK
AIMS To stimulate debate and discussion regarding the rationale for introducing health policies as well as optimal ways to assess their impact		
SPEAKER	Simon Hurding, UK <i>Lessons learnt in Scotland with introducing policies to improve the quality and efficiency of prescribing – Policy versus Polypharmacy</i>	
P10F.1	Ana Araújo, National Authority of Medicines and Health Products (Infarmed, I.P.), Lisbon, Portugal <i>Effect of tobacco cessation policies in the consumption of anti-smoking medicines in Portugal</i>	
P10F.2	Hye-young Kwon, Mokwon University, Daejeon, South Korea <i>Changes in pharmaceutical expenditures with massive price cuts</i>	
P10F.3	Sabine Vogler, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute), Vienna, Austria <i>Analysis of out-of-pocket payments for medicines in Kyrgyzstan</i>	
P10F.4	Elaine Lazzaroni Moraes, Instituto Nacional de Câncer, Ministério da Saúde, Rio de Janeiro, Brazil <i>Out-of-tender medicines procurement in a Brazilian reference cancer institution</i>	
08:30 – 10:00	PARALLEL SESSION P11F <i>Citizen Science and DUR</i>	
MAIN AUDITORIUM C	CHAIR: Katja Taxis, The Netherlands	CHAIR: Janet Krska, UK
AIMS To discuss ways to involve patients and the general public into DUR.		
SPEAKER	Nicky Britten, UK <i>Patient and lay involvement in drug utilisation research</i>	
P11F.1	Velisha Perumal-Pillay, University Of KwaZulu-Natal, Durban, South Africa <i>Parents' and guardians' perceptions on availability and pricing of medicines and healthcare for children in eThekweni, South Africa – A qualitative study</i>	
P11F.2	Peter Mol, Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, The Netherlands <i>Media attention for drug safety issues. A survey of newspapers and social media in the Netherlands (2001 – 2015)</i>	
P11F.3	Peter Mol, Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, The Netherlands <i>Which patients and healthcare professionals are interested in an app for reporting adverse drug reactions and receiving drug safety information?</i>	
P11F.4	Johanna Meyer, School of Pharmacy, Sefako Makgatho Health Sciences University, Ga-Rankuwa, Pretoria, South Africa <i>Patients with type-2 diabetes attending a community health centre in Pretoria, South Africa: Do they know how to manage their chronic condition to improve future care?</i>	

08:30 – 10:00	PARALLEL SESSION P12F <i>Cardiovascular Therapy</i>	
ROOMS 6 & 7	CHAIR: Margaret Ryan, UK	CHAIR: Elisabetta Poluzzi, Italy
AIMS To report results of studies on DUR in the area of cardiovascular diseases.		
P12F.1	Giuseppe Roberto, Agenzia Regionale Di Sanità Della Toscana, Florence, Italy <i>NSAIDs utilization in a large cohort of Italian elderly with cerebro/cardiovascular disease</i>	
P12F.2	Janne Sepp, State Agency of Medicines, Estonia, Institute of Pharmacy, University of Tartu, Estonia <i>Co-prescribing of renin-angiotensin system (RAS) acting agents is decreasing in Estonia</i>	
P12F.3	Amanj Kurdi, University of Strathclyde, Glasgow, United Kingdom, University of Nottingham, Nottingham, UK <i>Factors predicting the addition of a second antihypertensive drug in treating hypertension – a longitudinal retrospective cohort study in the UK primary care setting</i>	
P12F.4	Adele Lallo, Department of Epidemiology, Lazio Regional Health Service, Roma, Italy <i>Adherence to evidence-based drug therapies after myocardial infarction: is geographic variation related to hospital of discharge or primary-care providers? Methodological challenges and policy perspectives</i>	
P12F.5	Katja Taxis, University of Groningen, Groningen, The Netherlands <i>Factors associated with physician adherence to prescribing guideline-recommended medications for acute coronary syndrome in Vietnam</i>	
P12F.6	Tanja Mueller, University Of Strathclyde, Glasgow, UK, NHS National Services Scotland, Edinburgh, UK <i>Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies</i>	

10:30 – 12:00	PARALLEL SESSION P13F <i>Patient Reported Outcome Measures</i>	
MAIN AUDITORIUM B	CHAIR: Marion Bennie, UK	CHAIR: Janet Krska, UK
AIMS To present an overview of PROMs in the context of medicines and explore the potential opportunities and challenges with collecting and analysing PROMs data to support data generation for the purpose of improved patient care.		
SPEAKER	Janet Krska, UK <i>PROMS – the patient voice in clinical decision making</i>	
P13F.1	Emma Dunlop Corcoran, University Of Strathclyde, Glasgow, UK <i>PROMs in cancer care – examination of the current evidence of collection and use in routine clinical practice</i>	
P13F.2	Roma Maguire, University of Strathclyde, Glasgow, UK <i>Enabling daily monitoring of chemotherapy toxicity: The Daily Chemotherapy Toxicity Self-Assessment Questionnaire (DCTAQ)</i>	
P13F.3	Hans Wouters, Dept. of Pharmacotherapy, -Epidemiology & -Economics, University Of Groningen, Groningen, The Netherlands, Dept. of General Practice And Elderly Care Medicine, University Medical Center Groningen, Groningen, The Netherlands <i>Long-term exposure to anticholinergic and sedative drugs and cognitive and physical function in later life</i>	
P13F.4	Janet Krska, Medway School of Pharmacy, UK <i>Complexity of medicine regimens and patient perceptions of medicine burden</i>	

10:30 – 12:00	PARALLEL SESSION P14F <i>New Medicines: Management of Innovations</i>	
MAIN AUDITORIUM C	CHAIR: Brian Godman, Sweden / UK	CHAIR: Margaret Ryan, UK
AIMS To stimulate debate and discussion regarding optimal ways to optimize the managed entry of new premium priced medicines that meet unmet need given increasing budgetary concerns.		
SPEAKER	Margaret Ryan, UK <i>Experiences in Scotland with managing the introduction of new medicines; role of drug utilization research and prescribing initiatives</i>	
P14F.1	Sabine Vogler, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute), Vienna, Austria <i>Shining some light on confidential arrangements: Relevance of discounts for pharmaceutical pricing in European countries</i>	
P14F.2	Brian Godman, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, United Kingdom; Division of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden <i>The implementation of managed entry agreements in Central and Eastern Europe: Findings and implications for future policies</i>	
P14F.3	Sabine Vogler, Pharmacoeconomics Department, Austrian Public Health Institute, Vienna, Austria, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Vienna, Austria <i>How do average prices of high-cost medicines in Europe develop in the years following marketing authorisation?</i>	
P14F.4	Gisbert W. Selke, Wissenschaftliches Institut der AOK, Berlin, Germany <i>Biologicals: Possibilities and limitations of efficiency gains through biosimilars. An analysis of the German market 2004–2016 using health care funds claims data</i>	

10:30 – 12:00	PARALLEL SESSION P15F <i>DUR Across the World</i>	
ROOMS 6 & 7	CHAIR: Katja Taxis, The Netherlands	CHAIR: Jane Robertson, WHO
AIMS In this unique session, researchers from across the globe will report on DUR studies. We will cover Brazil, Canada, Indonesia, Australia, South Africa and Kenya.		
P15F.1	Claudia Garcia Serpa Osorio-de-Castro, Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil <i>Essential medicines list implementation dynamics: a case study using Brazilian federal medicines expenditures</i>	
P15F.2	Daniala Weir, McGill University, Montreal, Canada <i>Medications prescribed, stopped and modified at hospital discharge and filled medications in the community: failure to follow in-hospital medication changes and adverse health outcomes 30-days post hospital discharge</i>	
P15F.3	Elfride Sianturi, University Of Groningen, Groningen, The Netherlands, Universitas Cenderawasih, Papua, Indonesia <i>Association between stigma, beliefs about medicines and adherence to antiretroviral therapy: a cross sectional study in people living with HIV (PLHIV) in Papua, Indonesia</i>	
P15F.4	Lisa Pont, Centre For Health Systems And Safety Research, University of Technology , Sydney, Australia <i>De-prescribing of antipsychotics in residential aged care</i>	

P15F.5	Johanita Burger, North-West University (Potchefstroom Campus), Potchefstroom, South Africa <i>Appropriate and non-medical use of methylphenidate by residence students at a South African tertiary institution</i>
P15F.6	Margaret Oluka, Department of Pharmacology & Pharmacognosy, School of Pharmacy, University of Nairobi, Nairobi, Kenya <i>Incidence and determinants of medication errors among paediatric in-patients at a rural referral hospital in Kenya</i>

SCIENTIFIC PROGRAMME PART V

13:00 – 14:30	SYMPOSIUM S4F <i>Predictive Analytics, Patient Level Drug Exposure</i>	
MAIN AUDITORIUM B	CHAIR: Gabriel Sanf��lix-Gimeno, Spain	CHAIR: Marion Bennie, UK
AIMS To illustrate the application of different predictive analytics approaches and methods to large individual level datasets to inform advancements in clinical practice.		
SPEAKER	Rolf Groenwold, The Netherlands <i>Predictive modelling in electronic health records to improve guideline adherence: an example of cardiovascular risk management</i>	
SPEAKER	Chris Robertson, UK <i>Using linked databases and predictive methods to identify individuals at high risk of a healthcare associated infection</i>	
SPEAKER	Gabriel Sanf��lix-Gimeno, Spain <i>Predicting adherence using electronic databases: methods and novel predictors</i>	

13:00 – 14:30	WORKSHOP W5F <i>Role of DUR in Comparative Effectiveness Research</i>	
MAIN AUDITORIUM C	CHAIR: Bj��rn Wettermark, Sweden	CHAIR: Catherine Sermet, France
AIM To discuss the role of DUR in comparative effectiveness research.		
SPEAKER	Petra Denig, The Netherlands <i>Linking drug prescription data to clinical outcomes: from group to individual treatment response</i>	
SPEAKER	Thomas Cars, Sweden <i>Electronic health records, propensity scores and sensitivity analyses in comparative effectiveness research</i>	

13:00 – 14:30	WORKSHOP W6F <i>Cross-National Comparison Guideline and Checklist</i>	
ROOMS 6 & 7	CHAIR: Monique Elseviers, Belgium	CHAIR: Veronika Wirtz, USA
AIMS - To briefly present the checklist and the Good Practice Guidelines for designing, conducting, reporting and reviewing CNC studies - To learn more about the sources of bias in conducting CNC studies by the practical use of the CNC checklist while reviewing a published CNC study - To discuss this experience during a panel discussion		
SPEAKER	Yared Santa Ana-Tellez, Spain / Mexico <i>Development of a checklist and good practice guideline for cross-national comparison (CNC) of drug utilization</i>	

SPEAKER	Monique Elseviers, Belgium <i>Presentation of the paper selected for the review and practical organization of the review process in the working groups</i>
SPEAKER	Robert Vander Stichele, Belgium <i>Panel discussion of the results of the review process and the problems encountered while using the CNC checklist</i>

14:45 – 16:00	POSTER WALK <i>Each poster has 3 minutes to present, followed by 2 minutes of discussion</i>
11. Antibiotics (B)	Chairperson: Ria Benko, Tatiana Chama Borges Luz
12. Cardiovascular (B)	Chairperson: Veronika Wirtz, Natalie Weir
13. Cancer and Biologicals (B)	Chairperson: Amanj Kurdi, Ylenia Ingrassiotta
14. Drug Policy (B)	Chairperson: Brian Godman, Augusto Guerra Junior
15. Elderly (B)	Chairperson: Lisa Pont, Luciane Lopes
16. Nervous System (B)	Chairperson: Peter Mol, Sieta De Vries
17. Adherence	Chairperson: Emma Dunlop Corcoran, Kristel Paque
18. Pregnancy and Paediatrics	Chairperson: Katja Taxis, Hedvig Nordeng
19. Surprising Others	Chairperson: Janet Krska, Tinne Dilles

16:00 – 17:30	KEYNOTE LECTURE K5F
MAIN AUDITORIUM B & C	CHAIR: Marion Bennie, UK
SPEAKERS	Katja Taxis, University of Groningen, The Netherlands, Veronika Wirtz, Boston University, USA & Lisa Pont, Centre For Health Systems And Safety Research, University of Technology, Sydney, Australia <i>Drug utilization and health policy from a global perspective</i>
	CLOSING CEREMONY
SPEAKER	Marion Bennie, University of Strathclyde, UK
POSTER PRIZES	Monique Elseviers, University of Ghent, Belgium

SOCIAL PROGRAM

Wednesday 15th November



The Welcome Reception will take place in the City Chambers, Glasgow on Wednesday, 15th November at 7.00 pm.

All conference delegates are invited to join for drinks & canapes. Attendees must register for the Welcome Reception in advance.

This Civic Reception is provided by the Lord Provost of Glasgow to welcome visiting delegates to the city of Glasgow. You will be met by the live sounds of the traditional Scottish bagpipes while you receive your welcome drink.

The unique event is hosted by Glasgow City Council and is held in the prestigious surroundings of the City Chambers which were opened in 1888. This Victorian masterpiece is recognized as one of the most beautiful buildings in the UK. Completed in 1888, it is an impressive symbol Glasgow's political strength.

Thursday 16th November

Enjoy an unforgettable EuroDURG Networking Dinner in the Glasgow Science Centre on Thursday, 16th November at 7.30 pm.

The dinner is an opportunity to relax and network with conference delegates. All attendees must register for the dinner in advance. The dress code is smart casual.

Receive a welcome drink on arrival and feel free to play with the various interactive exhibits before sitting down to a delicious meal. Following that, get into the swing of things by enjoying a traditional Scottish ceilidh.

Opened in June 2000 by Queen Elizabeth II, the Science Centre is situated on the Cycle waterfront – a vibrant place where historic Glasgow meets the modern city. With its three principal buildings (Science Mall, Glasgow Tower and IMAX cinema) it is one of Scotland's most popular visitor attractions.




CONFERENCE & EVENT LOCATION AND FACILITIES

GETTING HERE

Technology and Innovation Building, 99 George Street Glasgow G1 1RD
0141 444 7000 / tic-reception@strath.ac.uk

We are easily accessible by foot, if you like to avoid the traffic rush. Bike stands are also available outside the main entrance for all cycling enthusiasts.



The closest main train stations are:

- Glasgow Queen Street (0.4mi)
- Glasgow Central (0.9mi)


If you travel by bus, Buchanan Bus Station is 0.6 miles away and runs frequent services to Glasgow International Airport and all corners of the country.

The nearest car parks are just a short walk away:

- NCP, Montrose Street, G1 1RS (0.2mi)
- City Parking, Duke Street, G4 0UW (0.3mi)

WI-FI AND INTERNET

Wi-Fi is available throughout the Technology & Innovation Centre at no charge. To get online:



NO SMOKING

Smoking and the use of e-cigarettes is prohibited within all University buildings and within 15 feet (4.6m) of any University building entrance, doorway, stairs or covered areas where this distance is within University property.


CLOAKROOM


Cloakroom facilities are available at no cost. The University accepts no responsibility for items left unattended in the cloakroom, or in any other area of the building.

CONFERENCE VENUE FLOOR PLANS

You will enter the TIC building from George Street on Level 2.

LEVEL 2:





SOCIAL PROGRAM VENUES

The Welcome Reception on Wednesday 15th November is at Glasgow City Chambers, George Square, G2 1DU.

- The City Chambers are a 3-5 minute walk from the conference venue.

The EuroDURG Networking Dinner on Thursday 16th November is at Glasgow Science Centre, 50 Pacific Quay, G51 1EA.

- To travel by train, take the Low Level train from Glasgow Central Station for 3 stops (5 minutes) and alight at Exhibition Centre.
- Take the covered walkway and follow the signposts for *Glasgow Science Centre* (walk approximately 10 minutes)

LIST OF POSTER ABSTRACTS

	NO.	WALK	TITLE	PRESENTING AUTHOR
ANTIBIOTICS (A)	1-1	THU	Personalised feedback of prescribing data to primary care teams to drive improvement in antibiotic use in primary care in Scotland	William Malcolm
	1-2	THU	Are pharmacist's good knowledge and awareness on antibiotics taken for granted? The situation in Albania and implications across countries	Brian Godman
	1-3	THU	Compliance to the Primary Health Care Treatment Guidelines and the Essential Medicines List in the Management of Sexually Transmitted Infections in Correctional Centres in South Africa: Findings and Implications	Brian Godman
	1-4	THU	A situational analysis of current antimicrobial governance, regulation and utilisation in South Africa	Johanna Meyer
	1-5	THU	Antibiotic utilisation in the Republic of Srpska – initiatives, their influence and implications	Ljubica Bojanić
	1-6	THU	What is the impact of mortality predictors in ICU patients with sepsis in a real case scenario?	Luciane Cruz Lopes
	1-7	THU	Initiatives to reduce non-prescription sales and dispensing of antibiotics in the Republic of Srpska; findings and implications	Ljubica Bojanić
	1-8	THU	Evaluation of Prescribing of Carbapenems and Piperacillin/Tazobactam in acute hospitals in NHS Scotland	William Malcolm
	1-9	THU	Prevalence of antibiotic prescription in paediatric outpatients in Italy: the role of local health districts and primary care physicians in determining variation	Adele Lallo
	1-10	THU	Evaluation of self-medication with antibiotics among patients in the low and middle income	Anastasia Guantai
CARDIOVASCULAR (A)	2-1	THU	Comparative effectiveness of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in the Scottish atrial fibrillation population: the value of real world evidence	Giorgio Ciminata
	2-2	THU	Use of direct oral anticoagulants after market entry of edoxaban: A Danish nationwide drug utilization study	Maja Hellfritzs
	2-3	THU	An investigation into the utilisation and prescribing patterns of the direct oral anticoagulants compared to warfarin in the community setting in England.	Andrew MacFarlane
	2-4	THU	Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications	Dorothy Aywak
	2-5	THU	Variations in initiation with oral anticoagulants for atrial fibrillation in the region of Valencia: a multilevel analysis with real-world data.	Daniel Bejarano-Quisoboni
	2-6	THU	Trends in the use of combinations of substances for cardiovascular therapy. A longitudinal survey using claims data from Germany.	Irene Langner
	2-7	THU	Patterns of long-term use of cholesterol-lowering drugs in Tuscany	Rosa Gini
	2-8	THU	Utilisation and dispensing patterns of warfarin and DOACs in Wales and Northern Ireland	Amanj Kurdi
	2-9	THU	Pharmacoepidemiology of arterial hypertension in Semey region: analysis of pharmacotherapy and patient compliance to treatment.	Aigerim Musina
	2-10	THU	Knowledge of hypertension and its management among hypertensive patients on chronic medicines at primary health care public sector facilities in South Africa; findings and implications	Johanna Meyer

CANCER AND BIOLOGICALS (A)	3-1	THU	Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving long-term biological agents in a real-life setting	Luciane Cruz Lopes
	3-2	THU	Switch from epoetin originator to alpha biosimilar: Clinical efficacy of biosimilars on hemoglobin and safety in a population of patients on stable hemodialysis	Anna Bianca Calzona
	3-3	THU	Real-world data about biosimilar and originator somatropin use in Italian clinical practice: a population-based multiple databases study during the years 2009-2014	Ylenia Ingrassiotta
	3-4	THU	Changes in medication use in advanced cancer patients when death approaches. The international multicentre EPCS study	Kristel Paque
	3-5	THU	Impact of a regulatory intervention on the use of targeted oncologic drugs in the Ecuadorian public and private healthcare sector	Thierry Christiaens
	3-6	THU	Oncoematologic utilization of Rituximab: linking administrative with hospital pharmacy data for studying real world utilization of infusive antineoplastics	Giuseppe Roberto
	3-7	THU	Immunosuppressive therapy in transplanted patients: a descriptive analysis of common practice in the Lazio Region, Italy	Valeria Belleudi
	3-8	THU	Trastuzumab for metastatic breast cancer: Systematic review and meta-analysis	Augusto Afonso Guerra Junior
	3-9	THU	Cost-effectiveness of therapy with trastuzumab for metastatic breast cancer: How much are we paying for more for the benefit of a new technology?	Augusto Afonso Guerra Junior
DRUG POLICY (A)	4-1	FRI	Formulary management activities of public sector Pharmacy and Therapeutics Committees in the Gauteng Province of South Africa: An analysis of observations of Pharmacy and Therapeutics Committee meetings	Moliehi Matlala
	4-2	THU	Use of Scottish Therapeutics Utility EFIPPS searches in NHS Lothian to improve patient safety	Simon Hurding
	4-3	THU	Assessing the impact of changes in national antibiotic use in Scotland on Gram-negative resistance using the NHS Scotland Infection Intelligence Platform	William Malcolm
	4-4	THU	Aspects of medicines regulation in four Latin-American countries: a DURG LA cross-national study	Luciane Cruz Lopes
	4-6	THU	Protocols for the introduction and follow-up of new medicines in Sweden	Karl Högström
	4-7	THU	Severing selection decisions from the concept of essential medicines: expenditures with fibrates in the Brazilian Essential Medicines List	Claudia Garcia Serpa Osorio-de-Castro
ELDERLY (A)	5-1	THU	Anticholinergic exposure in primary care and in long-term care: differences in medications involved and intensity?	Maarten Wauters
	5-2	THU	How can health care pathways explain polypharmacy in France? A Longitudinal analysis between 2011 and 2014	Catherine Sermet
	5-3	THU	Defining optimal therapy for an older individual with multimorbidity proves challenging: results of a survey among pharmacists and geriatricians	Marie-laure Laroche
	5-4	THU	The chronicity of polypharmacy: duration of polypharmacy in a nationwide cohort of older adults	Jonas Wastesson
	5-5	THU	Criteria for adequate and inadequate drug prescribing in older adults near the end of life: European expert consensus	Lucas Morin
	5-6	THU	The impact of the number of medications on unplanned hospitalization and mortality in Swedish community-dwelling elderly	Ivana Ivanova

	5-7	THU	Measuring drug use in the last months of life of older adults through large administrative databases: results from a feasibility study in France	Lucas Morin
	5-8	THU	Advanced care planning and associated changes in medication use in newly admitted nursing home residents	Kristel Paque
	5-9	THU	Potentially inappropriate medication use among elderly, hospitalized patients	Ria Benko
NERVOUS SYSTEM (A)	6-1	THU	Reasons for (non)adherence of co-prescribing laxatives with opioids	Liset Van Dijk
	6-2	THU	Use of tramadol among long-term opioid users in Denmark	Faruk Coric
	6-3	THU	Long-acting injectable antipsychotics: determinants of prescription and continuity of treatment in a Northern Italy area	Ippazio Cosimo Antonazzo
	6-4	THU	Patient factors associated with SSRI dose for depression treatment in general practice: a primary care cross sectional study	Chris Johnson
	6-5	THU	Prescribing trends of antipsychotic medications in Ireland primary care from 2005-2015	MaryJo MacAvin
	6-6	THU	Trends in opioid prescribing in Dutch general practices	Yvette Weesie
	6-7	THU	Trends in psychostimulant drug use among adults in the Netherlands	Catharina Schuiling-Veninga
DIABETES	7-1	THU	Dose adjustment of metformin in elderly patients with diabetes and impaired renal function	Jan Hasselström
	7-2	THU	Quality of life of patients in type 1 diabetes in use of insulin glargine versus NPH: Systematic review	Augusto Afonso Guerra Junior
	7-3	THU	Sociodemographic characteristics of type 1 diabetes' patients using insulin glargine in a state in Brazil: Are there barriers in access?	Augusto Afonso Guerra Junior
	7-5	THU	Pregabalin prescribing patterns in a private healthcare sector setting in South Africa	Ilse Truter
	7-6	THU	Evaluation of HbA1c in relation to prescription costs for oral diabetes medicine in the treatment of type 2 diabetes patients in the county of Östergötland, Sweden	Morgan Edström
	7-7	THU	Pharmacist-led self-management interventions to improve diabetes outcomes. A systematic literature review and meta-analysis.	Linda Van Eikenhorst
	7-8	THU	Measuring the quality and the financial impact of antidiabetic drug use trends in Europe: A cross-country comparison in 2015	António Teixeira Rodrigues
	7-9	THU	Pattern of use of incretin-based medicines in a large sample of the Italian general population	Giuseppe Roberto
INTERVENTIONS	8-1	THU	Introducing Academic Detailing in primary care in Norway	Harald Langaas
	8-2	THU	Development of an interactive data visualization comparing medicines use within the National Health Service in Scotland to support identification of unwarranted variation and improve effectiveness and efficiency.	Stuart Mctaggart
	8-4	THU	Prescribing patterns of physicians working in both the direct and indirect treatment sectors in Iran; findings and implications	Brian Godman
	8-5	THU	Ongoing initiatives in Scotland to improve the quality and efficiency of prescribing in ambulatory care	Brian Godman
	8-6	THU	Use of prescribing quality indicators for patients with type 2 diabetes in primary care audit and feedback: a pilot study	Petra Denig
	8-7	THU	Prescribing practices in primary care from a physician perspective: A descriptive pilot study	Naldy Parodi Lopez

	8-8	THU	Medicines Reconciliation at the Community Mental Health Team and General Practice Interface	Chris Johnson
	8-9	THU	Quality Improvement tools to improve the safe use of high risk medicines- a theory based evaluation	Natalie Weir
	8-10	THU	Improving the communication skills of pharmacy technicians in the outpatient pharmacy using an online feedback intervention: the COM-MA project	Marcia Vervloet
RESPIRATORY AND SAFETY	9-1	THU	Therapeutic ratios predict asthma control in the ASTROLAB cohort	Manon Belhassen
	9-2	THU	How often do asthma patients claim prescribed therapy?	Manon Belhassen
	9-3	THU	Adherence to long-acting bronchodilators after discharge for COPD: how much of the geographic variation is attributable to the hospital of discharge and how much to the primary care providers? A cross-classified multilevel design	Adele Lallo
	9-4	THU	Assessing LABA safety in routine asthma care from the ASTROLAB cohort: the need to look at detailed patterns of use	Eric Van Ganse
	9-5	THU	Determinants for healthcare professionals to take action on Direct Healthcare Professional Communications (DHPCs)	Petra Denig
	9-6	THU	A real world evaluation of the clinical effectiveness, safety and direct medical expenditure of high intensity statin therapy in high risk patients: A study protocol	Amanj Kurdi
	9-7	THU	Awareness among European healthcare professionals of four recent drug safety issues	Peter Mol
	9-8	THU	Communication on safety of medicines in Europe: Current practices and general practitioners' awareness and preferences	Petra Denig
	9-9	THU	An analysis of patient reports of adverse drug reactions (ADRs) via the UK Yellow Card scheme	Janet Krska
	9-10	THU	Impact of a pharmacist-driven pharmacovigilance system in a secondary hospital in the Gauteng Province of South Africa	Johanna Meyer

	No.	WALK	TITLE	PRESENTING AUTHOR
ANTIBIOTICS (B)	11-1	FRI	Investigating Orthopaedic Surgical Prophylaxis Changes and Post-op Acute Kidney Injury in NHS Grampian – using NHS Scotland Infection Intelligence Platform	Eilidh Fletcher
	11-2	FRI	Development of Clinical Decision Support (CDS) Mobile App for Antimicrobial Prescribing	William Malcolm
	11-3	FRI	Evaluating initial antimicrobial use in an adult medical intensive care unit at an academic teaching hospital in Pretoria, South Africa	Brian Godman
	11-4	FRI	An Observational Study of Antibiotic Therapy in Women Diagnosed with Peripartum Sepsis	Nouf Abutheraa
	11-5	FRI	Antibiotic consumption in Serbia	Vesela Radonjic
	11-6	FRI	Polypharmacy partnership: patient, general practitioner & prescribing advisor Successful delivery of polypharmacy reviews for at-risk patients in a Scottish Deep End Practice	Joanna Johnson
	11-7	FRI	Building a national Infection Intelligence Platform to improve antimicrobial stewardship and drive better patient outcomes – the Scottish Experience.	William Malcolm

	11-8	FRI	Point prevalence survey of antimicrobial utilisation in an academic hospital in the Gauteng province, South Africa	Johanna Meyer
	11-9	FRI	Cross national comparison of paediatric antibiotic use	Maria Matuz
CARDIOVASCULAR (B)	12-1	FRI	Utilisation and prescribing patterns of direct acting oral anticoagulants (DOACs) in the Scottish primary care setting	Rachel Mccafferty
	12-2	FRI	Persistence of statins therapy in Brazil and Scotland	Renata Nascimento
	12-4	FRI	Safety and clinical effectiveness of direct oral anticoagulants in patients with atrial fibrillation in Scotland	Tanja Mueller
	12-6	FRI	Adherence to chronic antihypertensive medication by patients managed at primary health care facilities in a rural district of Limpopo Province, South Africa	Johanna Meyer
	12-7	FRI	Amiodarone monitoring in primary care: Pilot study	Chris Johnson
	12-8	FRI	Utilisation and impact of community-based antiplatelet therapy on outcomes in patients following Acute Coronary Syndrome in Scotland during 2012-2014	Grant Wyper
	12-9	FRI	Statins use in primary care of the unified health system (SUS) – Brazil	Renata Nascimento
	12-10	FRI	The effect of health care professional-led interventions to modify lifestyle in people with hypertension – a systematic review	Indre Treciokiene
CANCER AND BIOLOGICALS (B)	13-1	FRI	Evaluation of health direct costs associated with the use of biosimilar and originator erythropoiesis stimulating agents (ESAs): An Italian, multi-Regional, population based study	Ylenia Ingrassiotta
	13-2	FRI	Federal purchases of the infliximab in Brazil: An analysis of the period 2007-2015	Claudia Garcia Serpa Osorio-de-Castro
	13-3	FRI	Antineoplastic agents of greater impact on medicine expenditures in Brazil's National Cancer Institute	Elaine Lazzaroni Moraes
	13-4	FRI	Comparing utilisation of subcutaneous biologics delivered through homecare services in a cohort of patients with rheumatic diseases	Tanja Mueller
	13-5	FRI	Defining a population of castrate resistant prostate cancer (CRPC) patients using record linkage of routine healthcare datasets within Greater Glasgow & Clyde (NHS GGC)	Kelly Baillie
	13-6	FRI	Comparing clinical trial populations to real world patients in the West of Scotland – experience in treatments for advanced (unresectable or metastatic) melanoma	Julie Clarke
	13-7	FRI	Utilization of biological drugs for the treatment of rheumatoid arthritis in Tuscany, Italy	Giuseppe Roberto
	13-8	FRI	Validation of the use of administrative data sources for the study of pharmacoutilization of cancer therapies	Claudia Bartolini
DRUG POICY (B)	14-1	FRI	First case of disinvestment using real-world evidence in Brazil; implications for the future	Augusto Afonso Guerra Junior
	14-3	FRI	Access to medicines in State of Minas Gerais - Brazil: analysis from different dimensions	Juliana Alvarez
	14-4	FRI	Description of Medicines Prices Websites in Five South American Countries	Robert Vander Stichele
	14-5	FRI	Has Brazil abandoned the EM concept? Developments of the Brazilian National Essential Medicines List, lessons learnt and perspectives	Claudia Garcia Serpa Osorio-de-Castro
	14-6	FRI	Description of medicines public procurement websites for some Latin America countries	Angela Acosta
	14-7	FRI	Electronic Prescription Data to Improve Primary Care Prescribing (EPIPP)	Sean MacBride-Stewart

ELDERLY (B)	15-1	FRI	Economic evaluation of a physician-implemented, structured medication review screening tool in older hospitalised patients in Ireland	Gary O'Brien
	15-2	FRI	The epidemiology of polypharmacy in older adults: a nationwide, longitudinal study of 1.7 million people over 3 years	Lucas Morin
	15-3	FRI	Quality assessment of pharmacotherapy in outpatients with chronic kidney disease in the Netherlands: a pilot study	Petra Denig
	15-4	FRI	Drug-drug interactions among old people with dementia	Eva Sönnnerstam
	15-5	FRI	Electronic assessment of the anticholinergic exposure using the MARANTE scale	Maarten Wauters
	15-6	FRI	Limitations in recording polypharmacy among older people in Greece	Paraskevi Papaioannidou
	15-7	FRI	Sustainable Implementation of Polypharmacy reviews as part of integrated care at Scale	Alpana Mair
NERVOUS SYSTEM (B)	16-1	FRI	Signs of deprescribing in nursing home residents evolving towards worse physical and mental health	Ivana Ivanova
	16-2	FRI	Opioid maintenance therapy in France: high-dosage buprenorphine still predominant despite a high increase in methadone use: results from the 2009-2015 UTOPIA study	Sandy Maumus-Robert
	16-3	FRI	Follow-up of patients who start with a benzodiazepine in general practice: prevalence and reasons for guideline non-adherence	Liset Van Dijk
	16-4	FRI	Burden of disease, healthcare pathways and costs of multiple sclerosis through Italian real-world data on 10 million inhabitants	Carlo Piccinni
	16-5	FRI	Changing patterns of meprobamate-containing combination analgesic prescribing in South Africa	Johanita Burger
	16-6	FRI	Opioid prescribing patterns in South Africa: A database study	Johanita Burger
	16-7	FRI	Consumption of anxiolytics and antidepressants in Serbia	Vesela Radonjic
ADHERENCE	16-8	FRI	Change in medicine utilisation patterns for methylphenidate and atomoxetine in the South African private health sector from 2005 to 2013	Johanita Burger
	17-1	FRI	Patient adherence to treatment for acute coronary syndrome in Vietnam: A prospective observational study.	Katja Taxis
	17-2	FRI	The proportion of patients covered (PPC) method	Lotte Rasmussen
	17-4	FRI	Lower risk of cardiovascular disease with higher refill adherence to lipid-lowering therapy in patients with type 2 diabetes	Sofia Axia Karlsson
	17-5	FRI	Relationship of Inhaler Adherence to Clinical Outcomes in Chronic Obstructive Pulmonary Disease	Job Van Boven
	17-6	FRI	Comparison of one-year non-persistence rates with dabigatran or rivaroxaban versus vitamin K antagonists in newly treated atrial fibrillation patients aged 75 and over: results from the French nationwide healthcare databases.	Géric Maura
PREGNANCY AND PAEDIATRICS	18-1	FRI	Utilization patterns of gonadotropins among women in the Lazio Region, Italy	Francesco Trotta
	18-2	FRI	Pediatric drug use of melatonin - a register linkage study in Sweden	Elin Kimland
	18-3	FRI	An audit of aminoglycosides use in the paediatric wards of a tertiary hospital in Kenya	Elias Onyango
	18-4	FRI	Polypharmacy in preterm neonates: prevalence and predictors.	Elisabetta Poluzzi
	18-5	FRI	Antidepressant use during pregnancy: a nationwide population-based study	Anne Bénard-larivière
	18-6	FRI	Prescribing trends of ADHD medications in Ireland primary care from 2005-2015	MaryJo MacAvin

	18-7	FRI	SafeStart - an intervention study to promote healthier pregnancies	Hedvig Nordeng
	18-8	FRI	Prevalence and characteristics of medicine use among pregnant women in a Kenyan hospital	Margaret Oluka
	18-9	FRI	Pregnancy use of prescription medication in Denmark -online available statistics 2000 to 2016	Maja Laursen
SURPRISING OTHERS	19-1	FRI	Prevalence of rheumatoid arthritis and associated chronic disease list conditions in the private health sector of South Africa	Johanita Burger
	19-2	FRI	Trajectories Of Long-term Exposure To Anticholinergic And Sedative Drugs: A Latent Class Growth Analysis	Hans Wouters
	19-3	FRI	Self-medication in various professional groups	Elyne De Baetselier
	19-4	FRI	Trends in prescribing proton pump inhibitors in the Netherlands between 2001 and 2015	Catharina Schuiling- Veninga
	19-5	FRI	Analysis and in-house development of an automated system for the management of pharmaceutical preparations in the Hospital	Enrica Lavezzini
	19-6	FRI	Power considerations for interrupted time-series analysis: A simulation study	Samuel Hawley
	19-7	FRI	Drug utilization in patients with liver cirrhosis	Rianne Weersink
	19-8	FRI	Pattern of Use of Intravitreal Drugs with Antiangiogenic Properties for Age-related Macular Degeneration and Other Vascular Retinopathies	Rosa Gini
	19-9	FRI	Translation and validation of a Danish version of the Medication-Related Quality of Life (D-MRQoL)Scale	Anna Birna Almarsdóttir

NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

[illegible]